Is BioCryst Pharmaceuticals Stock a Buy?

Mark Prvulovic, The Motley Fool
·5-min read
Is BioCryst Pharmaceuticals Stock a Buy?

Small-cap biotech BioCryst Pharmaceuticals (NASDAQ: BCRX) is among them, and its COVID-19 drug is currently in early stage clinical testing. While most companies working on a COVID-19 treatment have seen their shares jump, BioCryst has been a surprising underperformer so far this year. Is BioCryst a potential diamond in the rough, or is the company really just not that remarkable after all?